Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Stock Report

Market Cap: US$809.6m

Aclaris Therapeutics Management

Management criteria checks 2/4

Aclaris Therapeutics' CEO is Neal Walker, appointed in Jul 2012, has a tenure of 14.17 years. total yearly compensation is $3.38M, comprised of 18.2% salary and 81.8% bonuses, including company stock and options. directly owns 1.05% of the company’s shares, worth $8.49M. The average tenure of the management team and the board of directors is 1.8 years and 12 years respectively.

Key information

Neal Walker

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage18.22%
CEO tenure14.2yrs
CEO ownership1.0%
Management average tenure1.8yrs
Board average tenure12yrs

Recent management updates

Recent updates

Analysis Article • Feb 03

There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump

Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shares have continued their recent momentum with a 25% gain in the last...
Analysis Article • Dec 19

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 25% Share Price Surge Not Quite Adding Up

Despite an already strong run, Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shares have been powering on, with a gain of...
Analysis Article • Oct 31

Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 31%

Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shares have continued their recent momentum with a 31% gain in the last...
Analysis Article • Sep 04

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Aug 10

Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates

It's been a good week for Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders, because the company has just...
Analysis Article • Jun 12

Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26%

Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders would be excited to see that the share price has had a great...
Analysis Article • May 21

Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Apr 23

Some Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shareholders Look For Exit As Shares Take 31% Pounding

To the annoyance of some shareholders, Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shares are down a considerable 31% in...
Analysis Article • Mar 07

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) share price has dived 27% in the...
Seeking Alpha • Feb 11

Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule

Summary Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. The company’s lead asset, ATI-045, shows promising phase 2a results in atopic dermatitis, but skepticism remains due to past failures. Financially, Aclaris has sufficient cash for over 15 quarters, despite recent acquisitions and expenses. I recommend waiting for more data on ATI-045 before considering an investment in Aclaris. Read the full article on Seeking Alpha
Analysis Article • Nov 12

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Celebrations may be in order for Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders, with the analysts delivering...
Analysis Article • Aug 08

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 03

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Mar 07

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Despite an already strong run, Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shares have been powering on, with a gain of...
Analysis Article • Mar 01

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) just released its latest full-year results and things are looking bullish...
Analysis Article • Jan 19

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Those holding Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shares would be relieved that the share price has rebounded...

CEO Compensation Analysis

How has Neal Walker's remuneration changed compared to Aclaris Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$76m

Mar 31 2026n/an/a

-US$70m

Dec 31 2025US$3mUS$615k

-US$65m

Sep 30 2025n/an/a

-US$142m

Jun 30 2025n/an/a

-US$135m

Mar 31 2025n/an/a

-US$130m

Dec 31 2024US$1mUS$477k

-US$132m

Sep 30 2024n/an/a

-US$37m

Jun 30 2024n/an/a

-US$59m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$74kn/a

-US$88m

Sep 30 2023n/an/a

-US$115m

Jun 30 2023n/an/a

-US$105m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$6mUS$590k

-US$87m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$7mUS$567k

-US$91m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$71m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$2mUS$424k

-US$51m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$3mUS$500k

-US$114m

Compensation vs Market: Neal's total compensation ($USD3.38M) is about average for companies of similar size in the US market ($USD3.51M).

Compensation vs Earnings: Neal's compensation has increased whilst the company is unprofitable.

CEO

Neal Walker (56 yo)

14.2yrs
Tenure
US$3,375,591
Compensation

Dr. Neal S. Walker, D.O. & M.D., is Co-Founder of Aclaris Therapeutics, Inc. and serves as Chief Executive Officer & Chairman since February 2025. He joined firm in July 2012. At Aclaris Therapeutics, Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Neal Walker
Co-Founder14.2yrsUS$3.38m1.05%
$ 8.5m
Hugh M. Davis
President1.8yrsno data0.031%
$ 249.8k
Kevin Balthaser
Chief Financial Officer3.7yrsUS$1.49m0.13%
$ 1.0m
James Loerop
Chief Business Officer4.7yrsUS$1.45m0.13%
$ 1.1m
Roland Kolbeck
Chief Scientific Officer1.2yrsno data0.016%
$ 132.0k
William Roberts
Senior Vice President of Corporate Communications & Investor Relations1.7yrsno datano data
Matthew Rothman
General Counsel & Corporate Secretary4.3yrsno datano data
Steve Tucker
Executive Vice President of Project Leadership2.7yrsno datano data
Jesse Hall
Chief Medical Officer1.4yrsno data0.018%
$ 148.7k
Nina Samra
Senior Vice President of Clinical Operations1.8yrsno datano data
Meghan Dunsmore
Senior Vice President of Finance1.7yrsno datano data
Shaun Selness
Senior VPless than a yearno datano data
1.8yrs
Average Tenure
57yo
Average Age

Experienced Management: ACRS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Neal Walker
Co-Founder14.2yrsUS$3.38m1.05%
$ 8.5m
Hugh M. Davis
President1.8yrsno data0.031%
$ 249.8k
Vincent Milano
Independent Director6.7yrsUS$120.49k0.020%
$ 158.9k
Mark Bradshaw
Member of Advisory Boardno datano datano data
James Leyden
Member of Advisory Boardno datano datano data
Klaus Theobald
Member of Advisory Boardno datano datano data
Anand Mehra
Independent Director12yrsUS$120.49k0.49%
$ 4.0m
Guy Webster
Member of Advisory Boardno datano datano data
Christopher Molineaux
Lead Independent Director12.7yrsUS$141.99k0.047%
$ 382.5k
Kenneth Beer
Member of Advisory Boardno datano datano data
Leslie Baumann
Member of Advisory Boardno datano datano data
Andrew Ondo
Member of Advisory Boardno datano datano data
12.0yrs
Average Tenure
64yo
Average Age

Experienced Board: ACRS's board of directors are seasoned and experienced ( 12 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/21 21:47
End of Day Share Price 2026/09/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aclaris Therapeutics, Inc. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward NashCanaccord Genuity
Prakhar AgrawalCantor Fitzgerald & Co.
Donald EllisCitizens JMP Securities, LLC